Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q14767
UPID:
LTBP2_HUMAN
Alternative names:
-
Alternative UPACC:
Q14767; Q99907; Q9NS51
Background:
Latent-transforming growth factor beta-binding protein 2 plays a crucial role in the structural organization and assembly of elastic fibers, essential components of the connective tissue. This protein's involvement in the extracellular matrix's architecture underscores its importance in tissue development and integrity.
Therapeutic significance:
Linked to diseases such as primary congenital glaucoma, microspherophakia with or without secondary glaucoma, and Weill-Marchesani syndrome 3, understanding the role of Latent-transforming growth factor beta-binding protein 2 could open doors to potential therapeutic strategies. These conditions, characterized by eye abnormalities and connective tissue disorders, highlight the protein's clinical relevance.